This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kimura, M Articles by Soejima, R Search for Related Content PubMed PubMed Citation Articles by Kimura, M Articles by Soejima, R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 April; 37(4): 801-803

In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.

ABSTRACT

The in vitro and in vivo activities of three newly developed quinolone antimicrobial agents (sparfloxacin, tosufloxacin, and OPC-17116) were investigated. All three agents showed potent in vitro activities against Chlamydia psittaci, C. trachomatis, and C. pneumoniae with MICs that ranged from 0.031 to 0.125 micrograms/ml. These values were higher than those of minocycline (0.0075 to 0.015 micrograms/ml) but lower than those of erythromycin (0.25 to 0.5 micrograms/ml) and ofloxacin and ciprofloxacin (0.5 to 1.0 micrograms/ml). Mice were challenged with 10(5) inclusion-forming units of C. psittaci each by nasal instillation. All untreated control animals died within 7 days. The survival rates of mice treated with 40 mg of sparfloxacin, OPC-17116, or tosufloxacin per kg of body weight every 12 h for 7 days were 73, 73, and 60%, respectively, 7 days after the challenge. The survival rate of mice treated with ofloxacin at the same dosage was 53%. On the basis of the above results, we concluded that these three new quinolones might be useful in the treatment of chlamydial respiratory infections.

This article has been cited by other articles:

• Moola, S., Hagberg, L., Churchyard, G. A., Dylewski, J. S., Sedani, S., Staley, H. (1999). A Multicenter Study of Grepafloxacin and Clarithromycin in the Treatment of Patients With Community-Acquired Pneumonia. Chest 116: 974-983 [Abstract] [Full Text]